Entrada Therapeutics (TRDA)
(Delayed Data from NSDQ)
$15.80 USD
-0.58 (-3.54%)
Updated Jun 6, 2024 04:00 PM ET
After-Market: $15.80 0.00 (0.00%) 6:38 PM ET
3-Hold of 5 3
B Value A Growth A Momentum A VGM
Price, Consensus and EPS Surprise
TRDA 15.80 -0.58(-3.54%)
Will TRDA be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for TRDA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for TRDA
Wall Street Analysts Think Entrada Therapeutics (TRDA) Could Surge 37.08%: Read This Before Placing a Bet
New Strong Sell Stocks for March 18th
TRDA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Exelixis (EXEL) Posts Preliminary 2023 Results, to Cut 13% Jobs
Bayer (BAYRY) Elinzanetant Meets Goals in Late-Stage Studies
Amicus (FOLD) Issues Preliminary Revenue Results for FY23
Other News for TRDA
Entrada Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference
Two new option listings on May 30th
Insider Sale: Chief Scientific Officer of Entrada Therapeutics Inc (TRDA) Sells Shares
PTC Therapeutics rallies 18% on EU authorization update for Translarna
Entrada Therapeutics to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ